{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:19:04Z","timestamp":1788185944534,"version":"build-2803163510"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12185-026-04253-8","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:03:48Z","timestamp":1783998228000},"page":"449-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to comments on \u201cMeasurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan\u201d"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-3227","authenticated-orcid":false,"given":"Hirotaka","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhaeng","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"4253_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-026-04226-x","author":"RP Jayaswal","year":"2026","unstructured":"Jayaswal RP, Badyal RK, Ranawat RK. Letter comments on: \u201cMeasurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.\u201d Int J Hematol. 2026. https:\/\/doi.org\/10.1007\/s12185-026-04226-x.","journal-title":"Int J Hematol"},{"key":"4253_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s12185-025-04149-z","volume":"123","author":"H Matsui","year":"2026","unstructured":"Matsui H, Takizawa J, Kojima K, Tauchi T, Ikeda C, Aruga Y, et al. Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan. Int J Hematol. 2026;123:678\u201385.","journal-title":"Int J Hematol"},{"key":"4253_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64398-6","volume":"14","author":"Y Aruga","year":"2024","unstructured":"Aruga Y, Ikeda C, Matsushita H, Makita S, Fukuhara S, Munakata W, et al. The kappa\/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype. Sci Rep. 2024;14:13452.","journal-title":"Sci Rep"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04253-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:45Z","timestamp":1788184605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04253-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":3,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04253-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H Matsui has received lecture fees from AbbVie G.K., Otsuka Pharmaceutical, Sysmex Corporation, Nippon Becton Dickinson Co. Ltd., and GenMine Labs Corp., and consulting fees from AbbVie G.K.; J Takizawa has received research funding from Mitsubishi Tanabe Pharma Corporation and lecture fees from Janssen Pharmaceutical K.K.; K Kojima has received lecture fees from Janssen Pharmaceutical K.K., AstraZeneca K.K., AbbVie G.K., BeOne Japan G.K., and Nippon Shinyaku.; C Ikeda has received lecture fees from AbbVie G.K.; Y Aruga has received lecture fees from AbbVie G.K.; H Matsushita has received research funding from Nippon Becton Dickinson Co. Ltd., Sysmex Corporation, JEOL Ltd., MiRNDa Inc., Tosoh Corporation and lecture fees from AbbVie G.K.; R Suzuki has received research funding from Meiji Seika Pharma Co. Ltd. and lecture fees from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., AbbVie GK, and AstraZeneca K.K.; H Sakamoto is an employee of Sapporo Clinical Laboratory Inc.; R Takenaka, J Park, and T Morita are employees of AbbVie G.K.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}